LeMaitre Vascular (NASDAQ:LMAT) Downgraded to Market Perform Rating by Oppenheimer

Oppenheimer downgraded shares of LeMaitre Vascular (NASDAQ:LMATFree Report) from an outperform rating to a market perform rating in a research report sent to investors on Friday morning, MarketBeat.com reports.

LMAT has been the subject of several other reports. Wells Fargo & Company started coverage on LeMaitre Vascular in a research report on Thursday, February 13th. They set an “equal weight” rating and a $95.00 target price for the company. StockNews.com cut LeMaitre Vascular from a “buy” rating to a “hold” rating in a report on Friday, December 13th. Finally, Barrington Research cut LeMaitre Vascular from an “outperform” rating to a “market perform” rating in a report on Friday. Five analysts have rated the stock with a hold rating, four have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $95.25.

Get Our Latest Research Report on LeMaitre Vascular

LeMaitre Vascular Price Performance

Shares of LMAT opened at $91.85 on Friday. LeMaitre Vascular has a 1 year low of $62.39 and a 1 year high of $109.58. The firm has a market cap of $2.07 billion, a PE ratio of 50.19, a PEG ratio of 2.22 and a beta of 0.96. The stock’s fifty day moving average price is $96.90 and its two-hundred day moving average price is $94.66.

LeMaitre Vascular (NASDAQ:LMATGet Free Report) last released its quarterly earnings data on Thursday, February 27th. The medical instruments supplier reported $0.49 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.49. LeMaitre Vascular had a return on equity of 13.15% and a net margin of 19.40%. The company had revenue of $55.81 million for the quarter, compared to analyst estimates of $55.99 million. Sell-side analysts anticipate that LeMaitre Vascular will post 1.94 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in the company. Conestoga Capital Advisors LLC lifted its stake in shares of LeMaitre Vascular by 1.9% in the 3rd quarter. Conestoga Capital Advisors LLC now owns 1,978,351 shares of the medical instruments supplier’s stock valued at $183,769,000 after purchasing an additional 36,850 shares during the period. Copeland Capital Management LLC lifted its stake in shares of LeMaitre Vascular by 0.7% in the 4th quarter. Copeland Capital Management LLC now owns 1,172,015 shares of the medical instruments supplier’s stock valued at $107,990,000 after purchasing an additional 8,623 shares during the period. State Street Corp lifted its stake in shares of LeMaitre Vascular by 3.6% in the 3rd quarter. State Street Corp now owns 822,085 shares of the medical instruments supplier’s stock valued at $76,363,000 after purchasing an additional 28,525 shares during the period. Congress Asset Management Co. lifted its stake in shares of LeMaitre Vascular by 1.8% in the 4th quarter. Congress Asset Management Co. now owns 722,325 shares of the medical instruments supplier’s stock valued at $66,555,000 after purchasing an additional 13,009 shares during the period. Finally, Geode Capital Management LLC lifted its stake in shares of LeMaitre Vascular by 1.4% in the 4th quarter. Geode Capital Management LLC now owns 550,260 shares of the medical instruments supplier’s stock valued at $50,711,000 after purchasing an additional 7,737 shares during the period. Hedge funds and other institutional investors own 84.64% of the company’s stock.

LeMaitre Vascular Company Profile

(Get Free Report)

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.

Featured Articles

Analyst Recommendations for LeMaitre Vascular (NASDAQ:LMAT)

Receive News & Ratings for LeMaitre Vascular Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LeMaitre Vascular and related companies with MarketBeat.com's FREE daily email newsletter.